NASDAQ: REGN Shareholder Notice: Investigation Over Possible Securities Laws Violations by Regeneron Pharmaceuticals, Inc.

An investigation for investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares over potential securities laws violations by Regeneron Pharmaceuticals, Inc. was announced.

San Diego, CA — (SBWIRE) — 04/15/2022 — Regeneron Pharmaceuticals, Inc is under investigation over potential securities laws violations in connection with certain financial statements.

Investors who purchased shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

The investigation by a law firm focuses on whether a series of statements by Regeneron Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Tarrytown, NY based Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

In 2020, The U.S. Attorney’s office filed suit against Regeneron Pharmaceuticals, Inc.. The complaint alleged that Regeneron Pharmaceuticals, Inc. funneled tens of millions of dollars in kickbacks through a third-party foundation to ensure that few Medicare patients paid a co-pay on Eylea and that physicians who prescribed and purchased the drug did not have to collect Medicare co-pays from their patients. Regeneron Pharmaceuticals, Inc. allegedly paid these substantial sums only after confirming that the foundation needed the money to cover co-pays only for Eylea and not for competing drugs. The company’s payments would generate a handsome return on investment, or ‘ROI,’ in the form of Medicare payments for Eylea. Furthermore, senior company executives allegedly took extensive measures to cover up the scheme.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) closed on March 25, 2022, at $680.03 per share.

Those who purchased shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Christopher Clausen
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About The Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit: http://www.sbwire.com/press-releases/nasdaq-regn-shareholder-notice-investigation-over-possible-securities-laws-violations-by-regeneron-pharmaceuticals-inc-1356216.htm

Media Relations Contact

Christopher Clausen
Shareholders Foundation
Telephone: 1-858-779-1554
Email: Click to Email Christopher Clausen
Web: http://www.ShareholdersFoundation.com